Posted by Michael Wonder on 07 Apr 2021
AbbVie submits regulatory applications for Skyrizi (risankizumab) in psoriatic arthritis to FDA and EMA
7 April 2021 - Submissions supported by two Phase 3 studies in patients with active psoriatic arthritis in which Skyrizi demonstrated improved skin and joint symptoms and physical function, with a greater proportion of patients achieving minimal disease activity versus placebo.
AbbVie today announced that it has submitted applications seeking approval for Skyrizi (risankizumab-rzaa, 150 mg) to the U.S. FDA and for Skyrizi (risankizumab, 150 mg) to the EMA for the treatment of adults with active psoriatic arthritis.
